FDA Orange Book
Generic for Antabuse
Antabuse contains disulfiram. Orange Book status for every listed strength, the approved generic makers, and the listed patents and exclusivities.
Source: FDA Orange Book data file dated 2026-10-09. Publisher page
Yes. The generic name for Antabuse is disulfiram. 3 companies hold an active FDA approval (ANDA) for a generic version in the Orange Book. Therapeutic equivalence codes: AB.
Run it in Rivvi
Map Antabuse and your other top fills to their generics
Every strength in RxNorm, with brands that have no generic flagged.
Build the mapFree to start. Opens Rivvi, the AI workspace for healthcare teams.
Antabuse products in the Orange Book
| Form and route | Strength | Brand status | Brand TE | Active generics | Generic TE codes |
|---|---|---|---|---|---|
| tablet, oral | 250MG | Discontinued | None | 3 | AB |
| tablet, oral | 500MG | Discontinued | None | 2 | AB |
NDA 007883, held by TEVA WOMENS HEALTH INC. Active generics are ANDA products in the Orange Book prescription list with the same ingredient, dosage form, route and strength.
Approved generic disulfiram
| Company | ANDA | TE code | Approved | Strengths |
|---|---|---|---|---|
| SIGMAPHARM LABORATORIES LLC | 091619 | AB (A-rated, therapeutically equivalent) | March 28, 2011 | 250MG, 500MG |
| CHARTWELL MOLECULES LLC | 091563 | AB (A-rated, therapeutically equivalent) | December 31, 2012 | 250MG, 500MG |
| ALVOGEN INC | 091681 | AB (A-rated, therapeutically equivalent) | August 8, 2013 | 250MG |
Questions
Is there a generic for Antabuse?
Yes. The generic name for Antabuse is disulfiram. 3 companies hold an active FDA approval (ANDA) for a generic version in the Orange Book. Therapeutic equivalence codes: AB.
What is the generic name for Antabuse?
The active ingredient in Antabuse is disulfiram, per the FDA Orange Book.
What does a therapeutic equivalence code mean?
In the Orange Book, codes that start with A (such as AB) mean FDA considers the product therapeutically equivalent to the reference drug. Codes that start with B mean FDA does not, at this time, consider the product therapeutically equivalent.